SCHEMBL16260517

SCHEMBL16260517

CNC(=O)[C@H](C)CC(C)NO

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.35
MMP9 P14780 10/20 0.35
MMP8 P22894 6/20 0.35
MMP1 P03956 9/20 0.33
MMP3 P08254 8/20 0.33
MMP13 P45452 3/20 0.33
ADAM17 P78536 6/20 0.33
MMP14 P50281 4/20 0.33
MMP7 P09237 2/20 0.33
TNF P01375 2/20 0.33
MMP20 O60882 1/20 0.33
ADAMTS4 O75173 1/20 0.33
MMP10 P09238 1/20 0.33
MMP12 P39900 1/20 0.33
MMP15 P51511 1/20 0.33
MMP16 P51512 1/20 0.33
MMP25 Q9NPA2 1/20 0.33
MMP26 Q9NRE1 1/20 0.33
ADAMTS5 Q9UNA0 1/20 0.33
MMP24 Q9Y5R2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4660964 0.78 MMP9 (0.42) MMP2MMP9MMP8MMP1MMP3
SCHEMBL16300127 0.78 MMP9 (0.42) MMP2MMP9MMP8MMP1MMP3
SCHEMBL14365019 0.78 MMP9 (0.42) MMP2MMP9MMP8MMP1MMP3
SCHEMBL18950437 0.76 LMNA (0.39) MMP2MMP9MMP8MMP1MMP3
SCHEMBL23178017 0.74 MMP1 (0.37) MMP2MMP9MMP8MMP1MMP3
SCHEMBL8246851 0.73 USP2 (0.33) MMP2MMP9MMP8MMP1MMP3
SCHEMBL22343466 0.73 MEN1 (0.35) MMP2MMP9MMP8MMP1MMP3
SCHEMBL11320412 0.72 GABRR1 (0.40)
SCHEMBL17304535 0.71
SCHEMBL22343465 0.71 SMN1; SMN2 (0.37) MMP2MMP9MMP8MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140349989-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF ALZHEIMER'S INSTITUTE OF AMERICA (US) 2014-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349989-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF NFATC1, CD4, CD47 MMP2 581/4885MMP9 490/4885MMP8 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.